ADVERTISEMENT
ADVERTISEMENT
José Baselga, cancer, research, oncology, AstraZeneca, breast cancer, drugs, therapeutics, obituary, dies
José Baselga, Renowned Oncologist, Dies at 61
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
José Baselga, Renowned Oncologist, Dies at 61
José Baselga, Renowned Oncologist, Dies at 61

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

financial ties
More Scientists, Institutions with Links to Jeffrey Epstein
Catherine Offord | Aug 27, 2019 | 2 min read
Researchers continued to meet and accept funding from the wealthy donor even after he was convicted of sex crimes in 2008.
NIH Raises Concerns About Foreign Influence in Biomedical Research
Catherine Offord | Feb 8, 2019 | 2 min read
Information made public by US Senator Chuck Grassley reveals that a handful of allegations have recently been referred to federal investigators.
CDC Director Resigns Over Unresolved Conflicts of Interest
Shawna Williams | Jan 31, 2018 | 1 min read
Brenda Fitzgerald had drawn criticism for tobacco-related investments, among others.
Cali Academy to Cut Fossil Fuel Ties
Tracy Vence | Aug 26, 2015 | 1 min read
The executive director of the California Academy of Sciences says it’s “the right thing to do.”
Scientists Urge Museums to Cut Koch Ties
Bob Grant | Mar 24, 2015 | 2 min read
Dozens of researchers called on science and natural history museums to sever financial relationships with fossil fuel companies and philanthropists who fund climate change denying scientists and organizations.
Opinion: Bias Is Unavoidable
Lisa Cosgrove | Aug 7, 2012 | 4 min read
Simply disclosing conflicts of interest is not enough.
ADVERTISEMENT